Use of Angiotensin System Inhibitors Is Associated with Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma
Hao Liu(Shihezi University), Yves Boucher(Harvard University), João Incio(Harvard University), James Michaelson(Massachusetts General Hospital), Andrea Zanconato(Massachusetts General Hospital), Kohei Shigeta(Keio University), Vikram Deshpande(Beth Israel Deaconess Medical Center), Theodore S. Hong(Massachusetts General Hospital), William W. Ho(Harvard University), Keith D. Lillemoe(Harvard University), Matthias Pinter(Medical University of Vienna), Jonathan A. Crain(Massachusetts General Hospital), Kamila Naxerova(Harvard University), Cristina R. Ferrone(Cedars-Sinai Medical Center), Janet E. Murphy(Harvard University), David P. Ryan(East Carolina University), Daniella Dias-Santos(Massachusetts General Hospital), Ronald M. Evans(University of California San Diego), Michael Downes(Salk Institute for Biological Studies), Jeffrey W. Clark(Massachusetts General Hospital), Hang Lee(Massachusetts General Hospital), A. Jacobson(Massachusetts General Hospital), Theodoros Michelakos(Harvard University), Carlos Fernández-del Castillo(Massachusetts General Hospital)
Cited by 102
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
Increased Acute Myocardial Infarction Rates and Cardiovascular Risk Factors among Patients with Human Immunodeficiency Virus Disease
|The Journal of Clinical Endocrinology & Metabolism|2007|1.6k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k